|
US4197307A
(en)
|
1977-04-12 |
1980-04-08 |
Ciba-Geigy Corporation |
2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents
|
|
EP0377903A3
(de)
|
1989-01-09 |
1991-07-17 |
Bayer Ag |
Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
|
|
ES2240017T3
(es)
|
1999-09-30 |
2005-10-16 |
Pfizer Products Inc. |
Derivados de 6-azauracilo como ligandos de receptores tiroideos.
|
|
US6787652B1
(en)
|
1999-09-30 |
2004-09-07 |
Pfizer, Inc. |
6-Azauracil derivatives as thyroid receptor ligands
|
|
GB0015205D0
(en)
|
2000-06-21 |
2000-08-09 |
Karobio Ab |
Bioisosteric thyroid receptor ligands and method
|
|
EP1347959A1
(de)
|
2000-12-27 |
2003-10-01 |
Bayer Aktiengesellschaft |
Indol-derivate
|
|
EP1471049A4
(en)
|
2002-01-30 |
2006-08-16 |
Kissei Pharmaceutical |
NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF
|
|
WO2003094845A2
(en)
|
2002-05-08 |
2003-11-20 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
|
GB0327319D0
(en)
|
2003-11-24 |
2003-12-24 |
Pfizer Ltd |
Novel pharmaceuticals
|
|
FR2882750B1
(fr)
|
2005-03-03 |
2007-05-11 |
Pierre Fabre Medicament Sa |
Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
|
|
GB0513692D0
(en)
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
|
DK1919878T3
(da)
*
|
2005-07-21 |
2010-10-25 |
Hoffmann La Roche |
Pyridazinonderivater som thyroidhormonreceptoragonister
|
|
GB0608724D0
(en)
|
2006-05-03 |
2006-06-14 |
Karobio Ab |
Novel Pharmaceutical Compositions
|
|
GB0610322D0
(en)
|
2006-05-24 |
2006-07-05 |
Karobio Ab |
Novel pharmaceutical compositions
|
|
WO2008130637A1
(en)
|
2007-04-18 |
2008-10-30 |
New York University |
Hydrazide compounds as thyroid hormone receptor modulators and uses thereof
|
|
WO2009001359A2
(en)
|
2007-06-27 |
2008-12-31 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of pro-apoptotic genes
|
|
TW200906823A
(en)
|
2007-07-16 |
2009-02-16 |
Lilly Co Eli |
Compounds and methods for modulating FXR
|
|
US8076334B2
(en)
|
2007-09-20 |
2011-12-13 |
Hoffmann-La Roche Inc. |
Prodrugs of thyroid hormone analogs
|
|
FR2933979B1
(fr)
|
2008-07-15 |
2012-08-24 |
Pf Medicament |
Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
|
|
RU2527948C2
(ru)
|
2009-04-20 |
2014-09-10 |
Мицубиси Танабе Фарма Корпорейшн |
Новый агонист бета рецептора тиреоидного гормона
|
|
WO2011038207A1
(en)
|
2009-09-25 |
2011-03-31 |
Metabasis Therapeutics, Inc. |
Phosphorus-containing thyroid hormone receptor agonists and methods of use
|
|
SG11201402004YA
(en)
|
2011-11-14 |
2014-05-29 |
Cephalon Inc |
Uracil derivatives as axl and c-met kinase inhibitors
|
|
CN103130723B
(zh)
*
|
2011-11-30 |
2015-01-14 |
成都地奥制药集团有限公司 |
一种多聚(adp-核糖)聚合酶抑制剂
|
|
CN102898377B
(zh)
|
2012-02-14 |
2016-01-20 |
南京圣和药业股份有限公司 |
一类酞嗪酮衍生物及其用途
|
|
AR092872A1
(es)
|
2012-09-17 |
2015-05-06 |
Madrigal Pharmaceuticals Inc |
Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
|
|
KR102374499B1
(ko)
|
2014-04-11 |
2022-03-14 |
사이머베이 쎄라퓨틱스, 인코퍼레이티드 |
Nafld 및 nash 의 치료
|
|
CN107074823B
(zh)
|
2014-09-05 |
2021-05-04 |
基因泰克公司 |
治疗性化合物及其用途
|
|
CN105477636B
(zh)
|
2015-10-16 |
2019-09-17 |
厦门大学 |
使用阿维菌素及其衍生物治疗代谢疾病的方法
|
|
TWI757266B
(zh)
|
2016-01-29 |
2022-03-11 |
美商維它藥物有限責任公司 |
ＲＯＲ－γ調節劑
|
|
US11419878B2
(en)
|
2016-03-28 |
2022-08-23 |
Intercept Pharmaceuticals, Inc. |
Medicine obtained by combining FXR agonist and ARB
|
|
SMT202500241T1
(it)
|
2016-03-31 |
2025-07-22 |
Genfit |
Elafibranor per uso nel trattamento di colangite biliare primitiva
|
|
BR112018073460A2
(pt)
|
2016-05-25 |
2019-07-09 |
Akarna Therapeutics Ltd |
terapias combinadas usando moduladores do receptor farnesoide x (fxr)
|
|
WO2018027892A1
(en)
|
2016-08-12 |
2018-02-15 |
Eli Lilly And Company |
Amino pyrimidine ssao inhibitors
|
|
WO2018075650A1
(en)
|
2016-10-18 |
2018-04-26 |
Madrigal Pharmaceuticals, Inc. |
Methods of treating liver disorders or lipid disorders with a thr-beta agonist
|
|
US20210212968A1
(en)
|
2016-10-19 |
2021-07-15 |
Boehringer Ingelheim International Gmbh |
Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
|
|
WO2018103624A1
(zh)
|
2016-12-06 |
2018-06-14 |
江苏恒瑞医药股份有限公司 |
一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
|
|
JP7618384B2
(ja)
|
2017-02-21 |
2025-01-21 |
ジェンフィ |
Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
|
|
WO2018167103A1
(en)
|
2017-03-13 |
2018-09-20 |
Genfit |
Pharmaceutical compositions for combination therapy
|
|
WO2018170173A1
(en)
|
2017-03-15 |
2018-09-20 |
Metacrine, Inc. |
Farnesoid x receptor agonists and uses thereof
|
|
JP7266531B2
(ja)
|
2017-04-18 |
2023-04-28 |
ジェンフィ |
エラフィブラノール又はその誘導体と抗ｎａｓｈ剤、抗線維化剤又は抗胆汁うっ滞性剤の組合せ
|
|
WO2018208707A1
(en)
|
2017-05-08 |
2018-11-15 |
Neurovia, Inc. |
Methods and compositions for treating demyelinating diseases
|
|
US20210121493A1
(en)
|
2017-07-25 |
2021-04-29 |
Cedars-Sinai Medical Center |
Methods for treating liver diseases
|
|
CN111032884A
(zh)
|
2017-08-25 |
2020-04-17 |
基恩菲特公司 |
非酒精性脂肪性肝病、非酒精性脂肪性肝炎和/或肝纤维化的非侵入性诊断
|
|
WO2019053235A1
(en)
|
2017-09-15 |
2019-03-21 |
Genfit |
NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
|
|
EP3684954B1
(en)
|
2017-09-18 |
2025-11-26 |
Genfit |
Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
|
|
JP7264906B2
(ja)
|
2017-11-01 |
2023-04-25 |
ブリストル－マイヤーズ スクイブ カンパニー |
ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
|
|
EP3710599B1
(en)
|
2017-11-13 |
2024-07-17 |
Gilead Sciences, Inc. |
Method for staging liver fibrosis in nash patients
|
|
JP7156722B2
(ja)
|
2018-01-23 |
2022-10-19 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
置換ピリダジノン化合物
|
|
WO2019209738A1
(en)
|
2018-04-24 |
2019-10-31 |
Ph Pharma Co., Ltd. |
Use of neutrophil elastase inhibitors in liver disease
|
|
ES3029158T3
(en)
|
2018-06-12 |
2025-06-23 |
Xizang Haisco Pharmaceutical Co Ltd |
Thyroid hormone receptor agonists and uses thereof
|
|
CN112805005A
(zh)
|
2018-08-24 |
2021-05-14 |
拓臻股份有限公司 |
甲状腺素受体β促效剂化合物
|
|
EP3844156A4
(en)
|
2018-08-30 |
2022-06-08 |
Terns Pharmaceuticals, Inc. |
TREATMENT OF HEPATIC DISORDERS
|
|
NZ773110A
(en)
|
2018-09-18 |
2024-11-29 |
Terns Inc |
Compounds for treating certain leukemias
|
|
EA202190661A1
(ru)
|
2018-09-18 |
2021-08-13 |
Метакрайн, Инк. |
Агонисты фарнезоидного х-рецептора для лечения заболевания
|
|
CA3113373A1
(en)
|
2018-10-12 |
2020-04-16 |
InventisBio Co., Ltd. |
Thyroid hormone receptor agonists
|
|
TWI884745B
(zh)
|
2018-10-12 |
2025-05-21 |
美商拓臻股份有限公司 |
甲狀腺素受體β促效劑化合物
|
|
CN111320609A
(zh)
|
2018-12-13 |
2020-06-23 |
拓臻股份有限公司 |
一种THRβ受体激动剂化合物及其制备方法和用途
|
|
EP3897666A2
(en)
|
2018-12-17 |
2021-10-27 |
Mitopower LLC |
Nicotinyl riboside compounds and their uses
|
|
CN111484481A
(zh)
|
2019-01-26 |
2020-08-04 |
察略盛医药科技(上海)有限公司 |
哒嗪酮类衍生物、其制备方法及其在医药上的用途
|
|
CN113474335B
(zh)
|
2019-02-21 |
2024-12-03 |
南京瑞捷医药科技有限公司 |
化合物及其作为甲状腺激素受体激动剂的用途
|
|
KR20220017917A
(ko)
|
2019-05-08 |
2022-02-14 |
알리고스 테라퓨틱스 인코포레이티드 |
Thr-베타의 조절제 및 이의 사용 방법
|
|
WO2020228577A1
(zh)
|
2019-05-10 |
2020-11-19 |
深圳微芯生物科技股份有限公司 |
一种哒嗪酮衍生物及其应用
|
|
WO2020239076A1
(zh)
|
2019-05-29 |
2020-12-03 |
南京明德新药研发有限公司 |
作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
|
|
EP4003349A1
(en)
|
2019-07-23 |
2022-06-01 |
Novartis AG |
Combination treatment of liver diseases using fxr agonists
|
|
CN112409340B
(zh)
|
2019-08-21 |
2022-03-18 |
海创药业股份有限公司 |
卤素取代的苯醚类化合物及其用途
|
|
AU2020336272A1
(en)
|
2019-08-23 |
2022-04-14 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
WO2021050945A1
(en)
|
2019-09-12 |
2021-03-18 |
Terns, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
TW202128668A
(zh)
|
2019-12-16 |
2021-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
并環類衍生物、其製備方法及其在醫藥上的應用
|
|
US20210379043A1
(en)
|
2020-05-13 |
2021-12-09 |
Terns Pharmaceuticals, Inc. |
Combination treatment of liver disorders
|
|
US20210379040A1
(en)
|
2020-05-13 |
2021-12-09 |
Terns Pharmaceuticals, Inc. |
Combination treatment of liver disorders
|
|
AU2021359895A1
(en)
|
2020-10-15 |
2023-06-15 |
Eli Lilly And Company |
Polymorphs of an fxr agonist
|
|
CN114437034A
(zh)
|
2020-11-06 |
2022-05-06 |
深圳微芯生物科技股份有限公司 |
一种酞嗪类化合物的可药用盐、晶型及其制备方法
|
|
KR20230154806A
(ko)
|
2021-01-14 |
2023-11-09 |
엔요 파마 |
Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
|
|
PE20240097A1
(es)
|
2021-03-03 |
2024-01-18 |
Terns Pharmaceuticals Inc |
Compuestos agonistas beta del receptor de la hormona tiroidea
|
|
WO2022194278A1
(zh)
|
2021-03-19 |
2022-09-22 |
南京明德新药研发有限公司 |
双环苯酚类化合物及其应用
|
|
EP4429637A1
(en)
|
2021-11-11 |
2024-09-18 |
Terns Pharmaceuticals, Inc. |
Treating liver disorders with an ssao inhibitor
|
|
CN119013027A
(zh)
|
2021-11-11 |
2024-11-22 |
拓臻制药公司 |
用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合
|
|
PE20241327A1
(es)
|
2021-11-11 |
2024-06-26 |
Terns Pharmaceuticals Inc |
Tratamiento de trastornos hepaticos con un agonista del thr-beta
|
|
WO2023220404A1
(en)
|
2022-05-13 |
2023-11-16 |
Terns Pharmaceuticals, Inc. |
Treatment of non-alcoholic steatohepatitis
|